(Q46817245)

25 December 2017

title

Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate (English)

1 reference

25 December 2017

author name string

Roehrborn CG

series ordinal

1

1 reference

25 December 2017

publication date

9 May 2006

1 reference

25 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

25 December 2017

volume

9

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

121-125

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500849

exact match

0 references

cites work

Benign prostatic hyperplasia (the aging prostate).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Terazosin, doxazosin, and prazosin: current clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Determination of prostate volume by transrectal ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500849

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.PCAN.4500849

1 reference

25 December 2017

Dimensions Publication ID

1040134848

0 references

1 reference

25 December 2017